European mid-cap companies reported mixed financial results for the third quarter and the first nine months of the year. emeis saw a 3.5% increase in Q3 revenue to €1.53 billion while reaffirming its full-year profitability targets. PharmaMar also reported growth, with a 12% revenue rise over the first nine months. Conversely, TF1 Group experienced a 9% decline in revenue during the same period, driven by challenges in linear advertising.
Royalties and Zepzelca sales supported PharmaMar’s growth, while its profit fell; TF1, meanwhile, faced pressure from linear advertising and maintained its 2026 targets.
Read the full story